Stay up-to-date with the Dr. Reddy's Laboratories Stock Liveblog, your trusted source for real-time updates and thorough ...

The drug is currently approved for treating heavily treatment-experienced (HTE) adults with multi-drug resistant HIV.

Dr. Reddy’s and Hetero partner with Gilead Sciences to manufacture and distribute Lenacapavir for HIV treatment in LMICs.

Dr Reddy's Laboratories and Hetero sign non-exclusive, royalty-free agreements with Gilead Sciences to manufacture ...

Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved ...

Here is a list of stocks that are set to be in focus during Thursday's session, as participants return to trade after a day's ...

Hyderabad: Dr Reddy's Labs has informed in a BSE filing that Chirotech Technology Limited, UK a step down wholly owned ...

Lenacapavir is a US Food and Drug Administration (FDA) approved medication indicated for the treatment of HIV type 1 (HIV-1) ...

Dr Reddy’s Laboratories said it has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead ...

Dr Reddy's Laboratories and Hetero, along with other generic drug makers, enter into voluntary licensing agreements with ...

While Urinary Tract Infection UTI mostly causes urinary problems many wonder whether it can also lead to non-specific ...

Gilead Sciences signs voluntary licensing agreement with six pharma firms to produce generic lenacapavir: Our Bureau, New Delhi Thursday, October 3, 2024, 11:30 Hrs [IST] US-based ...